This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Decision Resources.Most Promising Emerging Vaccines Include Novartis's MenB and Wyeth's PCV13 as Combined Peak-Year Sales Could Exceed $4 Billion by 2022. Media Release: 17 Nov 2008. Available from: URL: http://www.decisionresources.com
Rights and permissions
About this article
Cite this article
Pneumococcal, meningococcal highest value vax sectors in future. Pharmacoecon. Outcomes News 567, 11 (2008). https://doi.org/10.2165/00151234-200805670-00020
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805670-00020